MyHep All

Velpatasvir will do this by attacking the NS5A protein which is another important molecule where the virus periodically does replication and assembly tasks. NS5A enzyme plays a vital role in the replication process. Thus, inhibiting NS5A by means abatement of new viral particles formation leading to the general drop in the level of replication and consequently the viral load.

Aware of this fact, Sofosbuvir and Velpatasvir show synergism which means their effect is increasing than the effect of each alone. They cover several genotypes of Hepatitis C virus. These two exponential drugs results in high fitness rates and desirable treatment responses in people affected by Hepatitis C.

Indicating treatment of chronic Hepatitis C virus infection in adults, MyHep All Tablet is prescribed to be used together with other antiviral medications based on the patient’s genotype and treatment history. It might be used to treat both the patients who have been administered the chikungunya virus for the first time and those who have received other therapies such as interferon and direct acting antiviral agents.

Working

Inhibition of Viral Replication:

The action of Sofosbuvir is directed against the regular functioning of the NS5B polymerase enzyme which is the most important enzyme in chain viral RNA replication.

Sofosbuvir has nucleotide analogue inhibitors by which it is incorporated into the viral RNA chain, which in result causes termination of RNA synthesis before its time.

The virus is no longer able to start it reproduction. As it has a shortage of genetic material to use in the process and this inhibits viral replication and reduces the amount of viral load in the body.

Disruption of Viral Assembly and Maturation:

Velpatasvir is the key factor that targets the NS5A protein which is being considered a vital part of replication, assembly, and the emergence of the virus.

Instead of NS5A, Velpatasvir blocks pathway of new viral import and prevents assembly and maturation of the mature corrupt virus from infected cells.

This also inhibits the production of mature viral particles and the development of immune escape making the body to fight back thereby curbing the spread of the virus within the liver and to neighboring cells.

Synergistic Antiviral Activity:

Sofosbuvir and Velpatasvir working together as all-in-one pill MyHep All Tablet provides catalytic antiviral activity against all previously described genotypes of the Hepatitis C virus.

The two drugs isolate the various points in the life cycle of the viral cycle, decorating the overall effectiveness of treatment by targeting each stage.

Reduction of Hepatitis C Virus Load:Reduction of Hepatitis C Virus Load:

The virus could not produce proteins or spread anymore thanks to the inhibition of its replication and assembly by MyHep All Tablet, reducing its magnitude.

These results in ‘virologic activity’ reduction and increase in ‘liver function’ that both happen later on. And then, the successful elimination of the virus can be seen as ‘SVR’ which means sustained virologic response.

Recommended Dosage

The MyHep All Tablet dose is recommended as one tablet at a time orally once a day.

The tablet can be swallowed with or without water. It should be taken with a full glass of water and it is ok to take it with or without food.

Duration of Treatment:

The span of therapy with the vaccine MyHep All Pan Tablet will rely on multiple parameters like the genotype of the Hepatitis C virus, prior treatment history, and the presence of liver cirrhosis.

In most cases the therapy periods vary from twelve to twenty four weeks on the basis of determining by healthcare provider according to individual patient factors.

Special Populations:

• Elderly Patients: No changes in dosage are typically made for the elderly.
• Renal Impairment: MyHep All Tablet can normally be used in the context of gentle to moderate renal impairment. Nevertheless, these patients with grave renal disease or ESRD it is better to be careful in using them.
• Hepatic Impairment: The MyHep All Tablet is strictly not valid in patients with the severe hepatic impairment (Child-Pugh Class C). Dose adjustment is not imperative for patients with limited hepatic impairment (Child-Pugh Class 1 or 2).

Adherence to Treatment:

Such patients should take drugs as prescribed by their primary care provider and under the exact instructions on dosage and treatment duration.

Despite the drug therapy is interrupted or not applied properly, which leads to the decrease in the procedure effectiveness and to an increase in the risk of treatment failure and virus reoccurrence.

Monitoring and Follow-Up:

The patients must have regularly monitoring during whole course of treatment with MyHep Tablet to assess the treatment response, liver function, and possible adverse effects.

Apart from the follow-up appointments with the healthcare provider, one has to make sure that the treatment will be altered to the demands of the patient.

Side Effects

• Headache: Treatment-associated headaches, from mild to moderate, can be expected at this stage.
• Fatigue: A few patients may complain of these discomforting symptoms of tiredness and fatigue.
• Nausea: Nauseous and stomach discomfort is very likely to happen.
• Insomnia: Having problems with sleeping or sleeping disorders such as insomnia may be relevant for some people.
• Diarrhea: Mild gastrointestinal symptoms such as diarrhea can appear. Read the given sentence. As the need to quickly disseminate health-related information and perform disease identification has become increasingly apparent, the use of telemedicine in public health emergencies has gained importance.
• Rash: The rash or excessive itching might be observed; however, they are extremely rare.
• Anemia: The blood hemoglobin may decline(drop) resulting in anemia in some instances.

Interaction

• Antacids: MyHep All tablet absorption may be inhibited by adsorbents containing aluminum or magnesium. One must be advised to take antacids containing adsorbents of some other metals instead.
• Rifampin: The effectiveness of MyHep All Tablet will be decreased if taken alongside rifampin.
• Certain HIV medications: Here you face inconvenience: several HIV drugs may interact with MyHep All Tablet and impede therapy efficacy.
• Herbal supplements: Different types of herbal medicine i.e., St. John’s wort etc. may cause an interaction with MyHep All Tablet.
• Other Hepatitis C medications: Interacting with MyHep All Tablet with a few more Hepatitis C medications has the possibilities of having certain undesired side effects.

When to avoid the use of this medicine?

• Pregnant Women: MyHep All tablet does not advise pregnant women because of harm to developing fetus risk. An informed choice is the first step towards this, and women of childbearing potential should use effective contraception during and after the treatment as recommended by their healthcare provider.
• Breastfeeding Mothers: Nurse mothers should also avoid breastfeeding while taking MyHep All Tablet as Sofosbuvir and Velpatasvir may be excreted into breast milk and thus create potential risks to infants.
• Severe Hepatic Impairment: MyHep Tablet All persons who have a severe liver disease (Child-Pugh Class C) should not take it because it may worsen the liver function.
• Known Allergy or Hypersensitivity: Persons having a confirmed sensitivity or allergic reaction to Sofosbuvir, Velpatasvir or any ingredients of MyHep All Tablet should not use this preparation.
• Children: MyHep All Tablet should be used only in persons aged 18 years and above, since it has not been established that the drug is safe and effective in the paediatric population.
• Concurrent Use with Contraindicated Medications: MyHeP All tablet may unfortunately interact with some of the medications being taken, and hence, concurrent use with prohibited drugs should be avoided. Now Patients have to tell the provider about all medications they are taking before treatment starts.